Should I Buy TLRY? TLRY 2026 Analysis

Should You Buy Tilray Brands Inc (TLRY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.850

1 Day change

-6.77%

52 Week Range

23.200

Analysis Updated At

2026/01/26

Tilray Brands Inc (TLRY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows some positive developments in international sales and gross margin improvement, the financial performance remains weak with declining net income and EPS. Additionally, the technical indicators and options data do not suggest a strong upward momentum. The lack of recent Congress trading data and no significant trading signals from Intellectia Proprietary Trading Signals further support a cautious approach.

Technical Analysis

The MACD histogram is negative and contracting (-0.0118), indicating bearish momentum. RSI is neutral at 44.196, and moving averages are converging, suggesting no clear trend. Key support is at 8.751, and resistance is at 9.91. The stock is trading below the pivot level of 9.33, which is a bearish signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, but the overall volume and open interest trends are not strong enough to confirm a significant upward move.

Technical Summary

Sell

Buy

Positive Catalysts

Expansion into Italy with Tilray Medical Italia, enhancing its European presence.
Strong growth in international medical cannabis sales (+36% YoY).
Gross margin improvement to 24.43% (+34.60% YoY).

Neutral/Negative Catalysts

Declining net income (-47.35% YoY) and EPS (-58.59% YoY).
Analysts maintain neutral ratings with reduced price targets, citing uncertainties around U.S. legislative outcomes.
Lack of significant insider or hedge fund activity.

Financial Performance

In Q2 2026, revenue increased by 3.11% YoY to $217.5M, driven by international sales. However, net income dropped by 47.35% YoY to -$44.93M, and EPS fell by 58.59% YoY to -0.41. Gross margin improved to 24.43% (+34.60% YoY), indicating some operational efficiency gains.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain neutral ratings with price targets reduced to $10 from $20. While they acknowledge growth in international sales and Canadian performance, concerns remain about U.S. legislative uncertainties and long-term cash flow transparency.

4 Analyst Rating

Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

0 Sell

Hold

Current: 8.420

Low

8.5

Averages

9.57

High

Current: 8.420

Low

8.5

Averages

9.57

High

Canaccord

Kenric Tyghe

Hold

initiated

$13

AI Analysis

2026-01-27

New

Reason

Canaccord

Kenric Tyghe

Price Target

$13

AI Analysis

2026-01-27

New

initiated

Hold

Reason

Canaccord analyst Kenric Tyghe initiated coverage of Tilray with a Hold rating and C$13 price target. The firm says that despite regulatory headwinds and structural inefficiencies, the Canadian cannabis market "remains a global benchmark for legal cannabis commercialization." Tilray is the largest cannabis company by revenue in Canada and the fourth largest craft brewer in the U.S., the analyst tells investors in a research note. Canaccord cites the "tough" beer market for the Hold rating.

Roth Capital

Neutral

downgrade

$20 -> $10

2026-01-20

Reason

Roth Capital

Price Target

$20 -> $10

2026-01-20

downgrade

Neutral

Reason

Roth Capital lowered the firm's price target on Tilray to $10 from $20 and keeps a Neutral rating on the shares after its Q2 results. With a re-acceleration in international sales, strong Canadian adult-use performance , and an inflection at CC Pharma, Tilray looks poised to enter a period of stronger growth, though the upside for Tilray, unfortunately, will be predominantly determined by U.S. legislative outcomes, the analyst tells investors in a research note. Tilray had been on the leading edge of intoxicating hemp products, particularly among larger manufacturers, which faces potential ban on November 13, 2026, unless extended, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TLRY

Unlock Now

TLRY Should I Buy

TLRY Should I Buy

Should You Buy Tilray Brands Inc (TLRY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch